Diagnosis of Gestational Diabetes Mellitus Will Be Flawed until We Can Measure Glucose
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Gestational diabetes mellitus (GDM) is defined by glucose intolerance that is first documented during pregnancy (1,). Maternal hyperglycemia that is less severe than that in diabetes mellitus is strongly associated with increased birth weight, risk of Caesarean delivery, and other adverse outcomes (2,). Diagnosis of GDM is important because the risk of adverse events is reduced by treatment (3, 4). Diagnosis of GDM depends exclusively on measurements of plasma glucose. Glucose is typically measured before and at fixed time points after an oral glucose load (5,). However, a diagnosis of GDM often is made or excluded based on a single measured glucose concentration above or below a defined threshold (6,). By contrast, outside of pregnancy, diagnosis of diabetes requires, in the absence of typical symptoms, documentation of hyperglycemia (by either glucose or hemoglobin A1c) on more than one occasion (7). The requirement for accurate glucose measurements for diagnosis of GDM is heightened by the fact that hemoglobin A1c is not an alternative to glucose measurements for diagnosis of GDM. A major source of preanalytical error in measuring glucose is loss of glucose from blood specimens through glycolysis occurring primarily in red and white blood cells (8,). Glucose is lost from whole blood samples at a rate of 5%–7% per hour at room temperature (8). Thus, loss of glucose at 1 h exceeds the desirable limit of total analytical error for glucose based on biological variation. This preanalytical loss of glucose poses a threat to the diagnostic sensitivity of testing for GDM. Moreover, variation in time to centrifugation of blood samples introduces variability in glucose results with resultant variability in likelihood of diagnosis of GDM. Sodium fluoride (NaF) is widely used to inhibit glycolysis, but it is inadequate. NaF does not stop glycolysis for the first 2 h or more after sample collection, and during the first 60–90 min the loss of glucose proceeds at the same rate with or without NaF (8, 9,). Glucose tolerance testing presents a special problem when the fasting and other samples are held at the point of care (POC) for ≥2 h until completion of the procedure (10). The AACC and American Diabetes Association (ADA) guideline on laboratory testing in diabetes (8,) addresses the handling of samples collected for measurement of glucose in the diagnosis of diabetes. The guideline recommends that samples be immediately immersed in an ice slurry and analyzed within 30 min of collection (8,). This is difficult to achieve in routine patient care, and evidence suggests that this recommendation is not always followed in testing for GDM (10, 11). A study in this issue of Clinical Chemistry addresses the problem that glycolysis presents in the diagnosis of GDM (12,). In a previous study (10,), some of the same authors compared results of GDM testing in which samples were handled either with their institution’s usual procedures, including use of NaF-containing blood tubes, or according to the ADA/AACC-recommended procedures (8,). The recommended sample-handling approach produced a 2.7-fold increase in the rate of diagnosis of GDM (10). The increase was entirely attributable to control of glycolysis. Now these authors have evaluated the potential of glucose meters, used at the point of care, to improve the diagnostic accuracy of testing for GDM by minimizing the loss of glucose before analysis (12,). Thus, they measured glucose in skin-puncture blood at the POC, with samples collected from patients in the fasting state and at 1 and 2 h after a 75-gram oral glucose load. Venous blood samples were collected at the same times, and handled strictly according the ADA/AACC guidelines; glucose in the venous plasma was measured in a laboratory nationally accredited according to ISO 15189. Linear regression analysis of the POC glucose results vs. the laboratory plasma glucose results was conducted using a randomly selected derivation cohort (n = 102). The resulting equations were used to calculate the predicted laboratory plasma glucose result corresponding to each POC capillary result in the remainder of the cohort (n = 100). For estimation of diagnostic accuracy of the glucose meters in the latter cohort, the predicted venous values were used rather than the actual meter results. For the reference standard for diagnosis of GDM, the authors used the glucose concentrations in the venous plasma samples. For both types of samples the same diagnostic criteria (6) were used. The diagnostic accuracy with the predicted venous plasma results was not as good as might be hoped: The diagnostic sensitivity was 80.4% (95% CI 67.6–89.8) and the diagnostic specificity was 86.4% (72.7–94.8). The positive and negative likelihood ratios for predicting a diagnosis of GDM (made by the reference standard) can be calculated to be 5.9 and 0.23, respectively, corresponding to moderate changes in post-test probability of GDM. The authors concluded that the
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Decrease in glucose concentration in the sample due to glycolysis is a serious and underappreciated problem (62,63).”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [62]
Citations
Cites
Hyperglycemia and adverse pregnancy outcomes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707943 · Cited by 5,563
International Association of Diabetes and Pregnancy Study Groups Consensus Panel (2010) · Diabetes Care · doi:10.2337/dc09-1848 · Cited by 5,390
Effect of Treatment of Gestational Diabetes Mellitus on Pregnancy Outcomes
Crowther, C. A., Hiller, J. E., Moss, J. R., McPhee, A. J., Jeffries, W. S., & Robinson, J. S. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042973 · Cited by 3,159
2. Classification and Diagnosis of Diabetes:Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s002 · Cited by 2,697
A Multicenter, Randomized Trial of Treatment for Mild Gestational Diabetes
Landon, M. B., Spong, C. Y., Thom, E., Carpenter, M. W., Ramin, S. M., Casey, B., Wapner, R. J., Varner, M. W., Rouse, D. J., Thorp, J. M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902430 · Cited by 2,122 · cited 1×
“Diagnosis of GDM is important because the risk of adverse events is reduced by treatment (3, 4).”
BackgroundSacks, D. B., Arnold, M., Bakris, G. L., Bruns, D. E., Horvath, A. R., Kirkman, M. S., Lernmark, A., Metzger, B. E., & Nathan, D. M. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2010.161596 · Cited by 1,360 · cited 13×
“A major source of preanalytical error in measuring glucose is loss of glucose from blood specimens through glycolysis occurring primarily in red and white blood cells (8).”
BackgroundResultInfluentialSelf-citationGestational diabetes mellitus: mechanisms, treatment, and complications
Johns, E. C., Denison, F. C., Norman, J. E., & Reynolds, R. M. (2018) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2018.09.004 · Cited by 828 · cited 1×
“Gestational diabetes mellitus (GDM) is defined by glucose intolerance that is first documented during pregnancy (1).”
BackgroundSacks, D. B., Arnold, M., Bakris, G. L., Bruns, D. E., Horvath, A. R., Kirkman, M. S., Lernmark, A., Metzger, B. E., & Nathan, D. M. (2011) · Diabetes Care · doi:10.2337/dc11-9998 · Cited by 718
Self-citationAcidification of blood is superior to sodium fluoride alone as an inhibitor of glycolysis
Gambino, R., Piscitelli, J., Ackattupathil, T. A., Theriault, J. L., Andrin, R. D., Sanfilippo, M. L., & Etienne, M. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2008.121707 · Cited by 160 · cited 3×
“It is unfortunate that CFE tubes are not universally commercially available for clinical use, while tubes with only NaF to inhibit glycolysis persist despite calls over the past decade to replace them with CFE tubes (8, 9, 11, 14).”
BackgroundComparative accuracy of 17 point-of-care glucose meters
Ekhlaspour, L., Mondesir, D., Lautsch, N., Balliro, C., Hillard, M., Magyar, K., Radocchia, L. G., Esmaeili, A., Sinha, M., & Russell, S. J. (2017) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816672237 · Cited by 127 · cited 1×
“Better results might have been obtained with a different meter, but that points to another danger in concluding that glucose meters can be used for diagnosis of GDM: Meters vary in analytical performance (13).”
Background
Cited by
A Clinical Update on Gestational Diabetes Mellitus
Sweeting, A., Wong, J., Murphy, H. R., & Ross, G. P. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnac003 · Cited by 928
Sacks, D. B., Arnold, M., Bakris, G. L., Bruns, D. E., Horvath, A. R., Lernmark, Å., Metzger, B. E., Nathan, D. M., & Kirkman, M. S. (2023) · Diabetes Care · doi:10.2337/dci23-0036 · Cited by 351
Self-citationSacks, D. B., Arnold, M. A., Bakris, G. L., Bruns, D. E., Horvath, A. R., Lernmark, Å., Metzger, B. E., Nathan, D. M., & Kirkman, M. S. (2023) · Clinical Chemistry · doi:10.1093/clinchem/hvad080 · Cited by 205
Self-citationBogdanet, D., O’Shea, P., Lyons, C., Shafat, A., & Dunne, F. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9113451 · Cited by 117
“The pre-analytical blood sampling protocol for pregnancy OGTT requires revision and standardisation [102].”
MethodFu, J. M., & Retnakaran, R. R. (2022) · EClinicalMedicine · doi:10.1016/j.eclinm.2022.101294 · Cited by 108
Metadata
- Authors
- Bruns, D. E., Metzger, B. E., & Sacks, D. B.
- Affiliations
- University of Virginia (US)
- Northwestern University (US)
- National Institutes of Health (US)
- Corresponding author
- Bruns, David E
- Venue
- Clinical Chemistry
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-02-01
- Volume
- 66
- Issue
- 2
- Pages
- 265-267
- ISSN
- 0009-9147 (ISSN-L)
- 1530-8561
- PMC
- PMC7055661
- OpenAlex
- W3006574392
- Semantic Scholar
- 6cda89fdbec87b85d7267a24008fd8c401efd307
- Cited by
- 30
- References
- 16
- Citations by year
- 2025: 4 · 2024: 6 · 2023: 6 · 2022: 5 · 2021: 3 · 2020: 6
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Clinical Chemistry (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Intramural Research Program
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
- Health Sciences › Health Professions › Medical Laboratory Technology › Clinical Laboratory Practices and Quality Control
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Neonatal Health and Biochemistry
- Keywords
- gestational diabetes mellitus, glucose measurement, pre-analytical errors, glycolysis, blood sample storage, sodium fluoride, point-of-care testing, glucose tolerance test, HbA1c, diagnostic sensitivity, sample handling, diagnostic thresholds, oral glucose tolerance test, gestational weight gain, maternal hyperglycemia
- MeSH terms
- Blood Glucose, Female, Glucose, Glucose Tolerance Test, Humans, Pregnancy, Prospective Studies, Diabetes, Gestational, Point-of-Care Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Diagnosis of Gestational Diabetes Mellitus Will Be Flawed until We Can Measure Glucose. https://app.cochat.ai/papers/10.1093/clinchem/hvz027
- The paper
- Bruns, D. E., Metzger, B. E., & Sacks, D. B. (2020). Diagnosis of Gestational Diabetes Mellitus Will Be Flawed until We Can Measure Glucose. Clinical Chemistry. https://doi.org/10.1093/clinchem/hvz027
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.